Annals of Hepato-Biliary-Pancreatic Surgery (한국간담췌외과학회지)

The Korean Association of Hepato-Biliary-Pancreatic Surgery (한국간담췌외과학회)
권호 표지

Analysis of Outcomes and Prognostic Factors Associated with Surgical Treatment Plus Postoperative Radiation Therapy for Stage II/III Pancreatic Cancer

  • Lee, Seok-Ho (Department of Radiation Oncology, Gacheon University Gil Hospital) ;
  • Lee, Seung-Heon (Department of Radiation Oncology, Gacheon University Gil Hospital) ;
  • Lee, Kyu-Chan (Department of Radiation Oncology, Gacheon University Gil Hospital) ;
  • Park, Yeon-Ho (Department of Surgery, Gacheon University Gil Hospital) ;
  • Kim, Gun-Kook (Department of Surgery, Gacheon University Gil Hospital) ;
  • Lee, Jeong-Nam (Department of Surgery, Gacheon University Gil Hospital) ;
  • Goo, Yang-Seo (Department of Internal Medicine, Gacheon University Gil Hospital) ;
  • Kim, Yeon-Seok (Department of Internal Medicine, Gacheon University Gil Hospital) ;
  • Shim, Sun-Jin (Department of Internal Medicine, Gacheon University Gil Hospital) ;
  • Shin, Dong-Bok (Department of Internal Medicine, Gacheon University Gil Hospital) ;
  • Kim, Jung-Ho (Department of Radiology, Gacheon University Gil Hospital) ;
  • Chung, Dong-Hae (Department of Pathology, Gacheon University Gil Hospital)
  • Published : 2010.09.30
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate treatment outcomes for patients with stage II/III pancreatic cancer who are treated with radiation therapy (RT) with or without chemotherapy (CTx) following surgery. Methods: We retrospectively analyzed data from 17 patients who underwent surgery and post-operative RT with or without CTx between January 2000 and December 2008. Seven patients (41%) had stage II cancer and 10 (59%) had stage III cancer. Most were male (13 of 17; 76.5%). Age at diagnosis ranged from 42 to 82 (median 69) years. Whipple's operation was done in 9 patients (53%), distal pancreatectomy in 7 (41%), and subtotal pancreatectomy in 1 (6%). All patients received RT using a three-dimensional RT technique to spare critical normal structures. Median radiation dose was 54 Gy (range, 50.4~55.8 Gy). Variable CTx regimens were combined in 10 patients (58.8%); 5-FU in 4, UFTE-G in 4, gemcitabine in 1, and xeloda in 1. Acute toxicity was evaluated according to RTOG toxicity criteria. Survival analysis was done using the Kaplan-Meyer method. Univariate and multivariate prognostic factor analysis were done, respectively, using a log-rank test and Cox's proportional hazards model. Results: The median follow-up period was 12.6 months. Locoregional and distant failures occurred in 8 (47.1%) and 8 patients (47.1%), respectively. Five patients (29.4%) developed both loco-regional recurrence and distant metastasis. The metastatic sites were liver in 4 patients, lung in 3, peritoneum in 1, and kidney in 1. Median overall survival (OS) was 12.6 months. The 1- and 2-year OS rates were, respectively, 58.8% and 24.5%. Median disease-free survival (DFS) was 8.3 months and the 1- and 2-year DFS rates were 46.3% and 30.9%, respectively. The 2-year OS was not different between RT and RT with CTx : survival rates were 28.6% and 17.5%, respectively (p=0.764). T stage and a postoperative CA 19-9 level of ${\geq}$180 U/ml were significant prognostic factors for OS in both univariate and multivariate analysis: the 2-year OS for T3 and T4 were 34.1% and 16.7%, respectively (p=0.0022), the 2-year OS for <180 and ${\geq}$180 U/ml were 32.5% and 0%, respectively (p=0.0142) Acute toxicities were RTOG grade 1 (G1) nausea in 1 patient (5.9%), G1 vomiting in 2 (11.8%), and G1-2 enteritis in 5 (29.4%). The hematologic toxicities were G1 leukopenia in 5 patients (29.4%), G2 leukopenia 1 (5.9%), G1 thrombocytopenia in 1 (5.9%), and G1~2 anemia in 6 (35.3%). Conclusion: Survival results of the present study are comparable to those in other reports with acceptable toxicity. Significant prognostic factors for overall survival in pancreatic cancer are tumor stage and postoperative CA 19-9 level.

Keywords

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. https://doi.org/10.3322/canjclin.57.1.43
  2. Wade TP, Halaby IA, Stapleton DR, Virgo KS, Johnson FE. Population-based analysis of treatment of pancreatic cancer and Whipple resection: department of defense hospitals, 1989-1994. Surgery 1996;120:680-685. https://doi.org/10.1016/S0039-6060(96)80017-1
  3. Korea National Statistical Office. 2007 annual report on the cause of death statistics. Daejeon: The Office; 2008.
  4. Calvo FA, Viere JC, Gunderson LL, Willett CG. Cancer of the pancreas. In: Chao KSC, Perez CA, Brady LW, eds. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.1574-1588.
  5. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. https://doi.org/10.1001/archsurg.1985.01390320023003
  6. Willett CG, Del Castillo CF, Shih HA, et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 2005; 241:295-299. https://doi.org/10.1097/01.sla.0000152016.40331.bb
  7. Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual. 6th ed. Chicago, IL: Springer; 2002.
  8. Dickler A, Abrams RA. Radiochemotherapy in the management of pancreatic cancer--part II: use in adjuvant and locally unresectable settings. Semin Radiat Oncol 2005;15:235-244. https://doi.org/10.1016/j.semradonc.2005.04.003
  9. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579. https://doi.org/10.1016/S1091-255X(00)80105-5
  10. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782. https://doi.org/10.1097/00000658-199912000-00006
  11. Neoptolemos JP, Dunn JA, Stocken DD, et al. European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-1585. https://doi.org/10.1016/S0140-6736(01)06651-X
  12. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66: 56-61. https://doi.org/10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6
  13. Kim K, Kim S, Chie EK, Kim SW, Bang YJ, Ha SW. Postoperative chemoradiotherapy of pancreatic cancer: what is the appropriate target volume of radiation therapy? Tumori 2005;91:493-497.
  14. Kim SW, Chun M, Kim MW, et al. The outcome of postoperative radiation therapy for patients with stage II pancreatic cancer (T3 or N1 disease). J Korean Soc Ther Radiol Oncol 2007;25:213-218.
  15. Desai S, Ben-Josef E, Griffith KA, et al. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys 2009;75:1450-1455. https://doi.org/10.1016/j.ijrobp.2009.01.023
  16. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracilbased chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-1026. https://doi.org/10.1001/jama.299.9.1019
  17. Kil WH, Kim DK, Noh SI, et al. Adenocarcinoma of the body and tail of the pancreas;treatment and prognosis. Korean J Hepatobiliary Pancreat Surg 2000;4:161-168.
  18. Brown MW, Ning H, Arora B, et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2006;65:274-283. https://doi.org/10.1016/j.ijrobp.2006.01.003